SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
BNTC reported First Quarter Fiscal Year 2027 results. The price and volatility reaction is pending.
BNTCearnings

Earnings reactions, page 2

Benitec Biopharma Inc. (BNTC) Q1 FY2027 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Net loss for the quarter ended September 30, 2026, was $12.9 million compared to a net loss of $9.0 million for the quarter ended September 30, 2025.
  • Net loss per basic and diluted share was $(0.26) for the quarter ended September 30, 2026, compared to $(0.22) for the quarter ended September 30, 2025.
  • Total expenses for the quarter ended September 30, 2026, were $14.5 million compared to $9.8 million for the quarter ended September 30, 2025.
  • Research and development expenses were $8.6 million for the quarter ended September 30, 2026, compared to $3.4 million for the quarter ended September 30, 2025.
  • General and administrative expenses were $5.9 million for the quarter ended September 30, 2026, compared to $6.4 million for the quarter ended September 30, 2025.
  • As of September 30, 2026, the Company had $176.5 million in cash and cash equivalents.

Guidance

  • BB-301 pivotal study design to be finalized in the first calendar quarter of 2027.
  • The company remains on track to begin the BB-301 pivotal trial in mid-2027.

Notes

Benitec plans to change its fiscal year-end for financial reporting from June 30 to December 31 commencing with its first periodic report following the Form 10-Q for the fiscal quarter ended September 30, 2026.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →